Lyrica: Advanced Neuropathic Pain Management and Control
| Product dosage: 150 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $1.43 | $43.00 (0%) | 🛒 Add to cart |
| 60 | $1.15 | $86.00 $68.80 (20%) | 🛒 Add to cart |
| 90 | $1.13 | $129.00 $101.48 (21%) | 🛒 Add to cart |
| 120 | $1.10 | $172.00 $132.44 (23%) | 🛒 Add to cart |
| 270 | $0.92
Best per cap | $387.00 $247.68 (36%) | 🛒 Add to cart |
| Product dosage: 75 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 60 | $0.80 | $48.16 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $72.24 $69.66 (4%) | 🛒 Add to cart |
| 120 | $0.73 | $96.32 $87.72 (9%) | 🛒 Add to cart |
| 270 | $0.60
Best per cap | $216.72 $162.54 (25%) | 🛒 Add to cart |
Synonyms | |||
Lyrica (pregabalin) is a prescription medication specifically formulated for the management of neuropathic pain, fibromyalgia, and as an adjunctive therapy for seizures in adults. It belongs to the class of drugs known as anticonvulsants or antiepileptics, functioning by calming overactive nerves in the body. This medication is designed to provide significant relief from chronic pain conditions that are often difficult to treat with standard analgesics. Its targeted mechanism offers a specialized approach for patients who have not found sufficient relief from other therapies, improving daily functioning and quality of life.
Features
- Active ingredient: Pregabalin
- Available in oral capsule form (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg) and oral solution
- Schedule V controlled substance
- Rapid absorption with peak plasma concentrations occurring within 1.5 hours
- Linear pharmacokinetics with dose-proportional increases in exposure
- Primarily excreted renally unchanged
- Manufactured under strict pharmaceutical quality control standards
Benefits
- Effectively reduces neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia
- Provides significant relief from fibromyalgia symptoms, including widespread pain and tenderness
- Decreases seizure frequency when used as adjunctive therapy in adults with partial-onset seizures
- Improves sleep quality and daily function in patients with chronic pain conditions
- Offers flexible dosing options to accommodate individual patient needs and response
- Demonstrated efficacy in multiple randomized, double-blind, placebo-controlled clinical trials
Common use
Lyrica is primarily prescribed for the management of neuropathic pain conditions, including diabetic peripheral neuropathy and postherpetic neuralgia (nerve pain following shingles). It is also FDA-approved for the treatment of fibromyalgia, a condition characterized by widespread musculoskeletal pain, fatigue, and tenderness. Additionally, it is used as adjunctive therapy for partial-onset seizures in adults. Some off-label uses include generalized anxiety disorder and certain types of chronic pain syndromes, though these applications should only be pursued under strict medical supervision.
Dosage and direction
The recommended dosage of Lyrica varies depending on the indication and individual patient response. For neuropathic pain associated with diabetic peripheral neuropathy: begin with 50 mg three times daily (150 mg/day), may be increased to 100 mg three times daily (300 mg/day) within one week based on efficacy and tolerability. For postherpetic neuralgia: start with 75 mg twice daily or 50 mg three times daily (150 mg/day), may be increased to 300 mg/day after one week, and if needed, to 600 mg/day after additional week. For fibromyalgia: begin with 75 mg twice daily (150 mg/day), may be increased to 150 mg twice daily (300 mg/day) within one week, and to 225 mg twice daily (450 mg/day) if needed. For epilepsy: start with 75 mg twice daily (150 mg/day), may be increased to maximum of 600 mg/day. Always take with or without food as directed by your physician, and do not suddenly discontinue without medical supervision.
Precautions
Patients should be monitored for the development of edema, particularly those with pre-existing cardiac conditions. Weight gain may occur and should be monitored regularly. Lyrica may cause dizziness and somnolence, therefore patients should be cautioned about operating machinery or driving until they gain experience with the medication. Abrupt discontinuation may lead to insomnia, nausea, headache, and anxiety. Patients with a history of drug abuse should be closely monitored as Lyrica may produce euphoria. Ophthalmological examinations are recommended for patients experiencing visual disturbances. Renal function should be assessed before and during treatment, with dosage adjustment necessary for patients with renal impairment.
Contraindications
Lyrica is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. The medication should not be used in patients with severe renal impairment (creatinine clearance <30 mL/min) without appropriate dosage adjustment. Concomitant use with thiazolidinedione antidiabetic agents is not recommended due to potential risk of edema and weight gain. Patients with a history of angioedema to other antiepileptic drugs should avoid Lyrica. The medication is not recommended during pregnancy unless clearly needed and under strict medical supervision.
Possible side effect
Common adverse reactions (≥5% and twice placebo rate) include dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, constipation, euphoric mood, balance disorder, increased appetite, and thinking abnormal. Less frequent but serious side effects may include angioedema, hypersensitivity reactions, increased risk of suicidal thoughts or behavior, peripheral edema, dizziness and somnolence that may impair physical and mental abilities, visual field defects, and weight gain. Musculoskeletal side effects including myalgia and arthralgia have been reported. Some patients may experience withdrawal symptoms upon discontinuation.
Drug interaction
Lyrica has minimal drug-drug interactions as it is not metabolized by cytochrome P450 enzymes and does not inhibit or induce these enzymes. However, concomitant use with central nervous system depressants including opioids, benzodiazepines, and alcohol may potentiate impairment of motor function and cognitive ability. When used with thiazolidinedione antidiabetics, there is increased risk of weight gain and peripheral edema. Gabapentin, a related compound, may have additive effects when used concurrently. ACE inhibitors may increase the risk of angioedema. Pregabalin may enhance the fluid-retaining effect of NSAIDs.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. If multiple doses are missed, contact your healthcare provider for guidance on resuming therapy. Maintaining consistent blood levels is important for optimal efficacy, particularly for seizure control.
Overdose
Signs of overdose may include increased severity of dose-related adverse effects, particularly drowsiness, sedation, confusion, restlessness, agitation, and depression. Severe cases may involve cardiac conduction abnormalities and respiratory depression. There is no specific antidote for pregabalin overdose. Treatment should be symptomatic and supportive, including gastric lavage if presented early. Hemodialysis may be effective in removing pregabalin from the bloodstream (approximately 50% removal in 4 hours). Maintain adequate airway and ventilation, and monitor cardiac function and vital signs.
Storage
Store Lyrica capsules and oral solution at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the cap tightly closed to protect from moisture. Do not store in bathroom or other damp areas. Keep out of reach of children and pets. Discard any unused medication after the expiration date. Do not flush medications down the toilet or pour into drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Lyrica is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will experience the same benefits or side effects. Always follow your healthcare provider’s instructions regarding dosage, administration, and monitoring. Do not adjust your treatment regimen without consulting your physician. This information is not exhaustive and does not replace the official prescribing information.
Reviews
Clinical studies demonstrate that Lyrica provides significant pain relief in approximately 40-50% of patients with diabetic neuropathy and postherpetic neuralgia, with number needed to treat (NNT) values ranging from 4 to 6 for various pain conditions. Patient-reported outcomes indicate improved sleep quality and daily functioning. Some patients report substantial improvement in quality of life, while others may experience side effects that limit tolerability. The medication has shown consistent efficacy across multiple large-scale clinical trials, though individual response varies. Long-term studies support maintained efficacy with continued use, though regular monitoring for adverse effects is recommended.